Macular Edema - A Pipeline Analysis Report

Overview of the drug development pipeline for macular edema

Macular edema refers to swelling or thickening of the macula due to build-up of fluid inside the macula. This distorts the vision as macula is made up of a thin layer of light-sensitive tissues in the center of the retina. Accumulation of fluid in macula through damaged blood vessels near the retina and abnormal leakage is consequent in the occurrence of macular edema. Also, diabetic retinopathy, a condition that inflicts people suffering from diabetes, is one of the primary reason for macular edema. Individuals undergoing eye surgery are also susceptible to inflammatory diseases that affect the eye and retinal blood vessels, resulting in macular edema. Patients suffer from symptoms such as wavy or blurry vision along with the inability to distinguish colors. Technavio’s market research analysts have predicted that with the rising incidences of inflammatory diseases affecting the eye and numerous damaging conditions leading to macular edema, the cardiovascular and metabolic disorders market will witness significant drug development of therapeutics for macular edema in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage followed by molecules in the Phase II stage. Our market research analysts have also identified that almost same amount of drug molecules are under the phase I/II, discovery, and phase III drug development stages. The landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of macular edema. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• NEUMEDICS
• NOVARTIS
• STEALTH BIOTHERAPEUTICS

Therapeutic assessment of the drug development pipeline for macular edema by route of administration

• Oral
• Intravitreal
• Topical
• Subcutaneous
• Intraocular
• Intravenous
• Suprachoroidal

The intravitreal route of administration involves the administration of therapeutic drug substances into the vitreous located near the retina. It has been observed that a significant amount of total therapeutics for macular edema are being developed for intravitreal RoA.

Therapeutic assessment of the drug development pipeline for macular edema by therapies employed

• Monotherapy
• Combination therapy

According to this pipeline analysis report, significant amount of therapies are being developed for macular edema in the form of monotherapy. In the current pipeline, 38 molecules are developed for monotherapy that uses a single drug to treat a particular disorder.

Technavio also offers customization on reports based on specific client requirement.